

Companion Animal Biotechnology Market Forecasts To 2034 – Global Analysis By Product Type (Diagnostic Products, Vaccines, Biologic Therapeutics, Genetic Testing Products, Cell Therapy Products, Gene Therapy Products, Regenerative Medicine Products and Microbiome-Based Products), Biotechnology Platform, Animal Type, Therapeutic Area, Distribution Channel, Diagnostic Technology, Application, End User and By Geography

<https://marketpublishers.com/r/C88639422A32EN.html>

Date: September 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: C88639422A32EN

Abstracts

According to Statistics MRC, the Global Companion Animal Biotechnology Market is accounted for \$32.3 billion in 2026 and is expected to reach \$57.5 billion by 2034 growing at a CAGR of 7.5% during the forecast period. The Companion Animal Biotechnology market focuses on advanced biological technologies used to enhance healthcare for pets, especially dogs and cats. Key areas include molecular and genetic diagnostics, vaccines, biologic treatments, regenerative therapies, cell-based treatments, gene technologies, and microbiome solutions. Market expansion is supported by rising pet ownership, higher spending on veterinary services, increasing emphasis on preventive healthcare, and demand for earlier and more precise disease identification. Developments in genomics, molecular biology, stem-cell research, and personalized veterinary medicine are broadening biotechnology applications. Growing investment in veterinary research and the increasing availability of advanced therapeutic and diagnostic solutions are creating additional opportunities for companion-animal biotechnology providers.

Market Dynamics:

Driver:

Increasing Prevalence of Chronic and Age-Related Diseases

A growing burden of chronic and age-related illnesses in dogs and cats is creating a stronger need for innovative biotechnology solutions. Companion animals increasingly experience conditions such as joint degeneration, osteoarthritis, cancer, inflammatory disorders, soft-tissue injuries, and chronic wounds that can require specialized long-term management. Technologies including stem cells, regenerative therapies, biologics, molecular diagnostics, and genomic approaches are expanding the available options for these difficult conditions. Regenerative treatments are particularly attractive for musculoskeletal problems because they may support tissue repair in addition to conventional symptom management. Consequently, the increasing complexity and prevalence of companion-animal diseases are encouraging veterinarians and owners to adopt advanced biotechnology-based approaches.

Restraint:

High Cost of Biotechnology-Based Veterinary Treatments

Expensive biotechnology solutions can limit the broader adoption of advanced companion-animal healthcare. Genetic analyses, molecular testing, biologics, cell-based treatments, and regenerative procedures commonly involve sophisticated laboratory systems, specialized personnel, and additional diagnostic or monitoring requirements. These factors increase the overall cost of veterinary care compared with conventional treatment options. Many pet owners may be unable or unwilling to pay for high-priced therapies, especially where pet insurance provides limited reimbursement. Veterinary practices in emerging economies can also encounter financial barriers when acquiring advanced equipment and developing the necessary technical capabilities. As a result, elevated costs can reduce accessibility, constrain adoption among price-sensitive customers, and restrict the expansion of biotechnology-based veterinary solutions.

Opportunity:

Development of Microbiome-Based Diagnostics and Therapeutics

Greater scientific knowledge of microorganisms living in companion animals is opening new avenues for biotechnology development. Studies of intestinal, oral, and skin microbiomes are providing insights into relationships between microbial communities, immune responses, inflammation, digestion, and various diseases. These discoveries can support microbiome-based diagnostics that identify microbial imbalances and enable the development of interventions such as probiotics, prebiotics, postbiotics, and

targeted microbial therapies. Biotechnology companies can capitalize by creating microbiome testing platforms and individualized treatment strategies for pets. As research generates stronger clinical evidence and sequencing becomes more affordable, microbiome technologies may transition from primarily research applications toward practical diagnostic and therapeutic products, expanding the commercial potential of companion-animal biotechnology.

Threat:

Uncertain Clinical Outcomes of Emerging Biotechnology

Variability in the clinical performance of emerging biotechnology solutions can pose a significant market threat. Treatments based on stem cells, regenerative medicine, microbiome modification, gene technologies, and advanced biologics may not produce uniform results among different breeds, species, disease conditions, or individual animals. When clinical outcomes are inconsistent or long-term safety remains uncertain, veterinarians may be reluctant to recommend newer technologies. Reports of treatment failures or adverse effects could further weaken confidence among professionals and pet owners. Developers may also encounter difficulties establishing standardized protocols and proving reliable clinical benefits. Consequently, biotechnology adoption could remain concentrated within specialized veterinary facilities instead of achieving broad acceptance across mainstream companion-animal healthcare.

Covid-19 Impact:

The COVID-19 outbreak initially disrupted the Companion Animal Biotechnology market by restricting veterinary services, reducing routine appointments, interrupting laboratory operations, and creating transportation and supply-chain challenges. Consequently, some vaccinations, diagnostic procedures, and non-emergency treatments were postponed. At the same time, the pandemic created new opportunities for veterinary biotechnology by increasing awareness of zoonotic infections and the importance of rapid molecular testing. Veterinary diagnostic laboratories adapted their capabilities to detect SARS-CoV-2 in animals and support broader public-health testing. Companion animals accounted for a substantial share of animal testing. These developments highlighted the value of veterinary diagnostics, disease surveillance, and One Health approaches, supporting longer-term biotechnology innovation.

The Diagnostic Products segment is expected to be the largest during the forecast period

The Diagnostic Products segment is expected to account for the largest market share during the forecast period, because biotechnology-based diagnostics are fundamental to early disease detection, preventive healthcare, and treatment monitoring in companion animals. Veterinary clinics increasingly rely on molecular tests,

immunodiagnostics, genetic testing, pathology, and other advanced diagnostic solutions to identify infectious, chronic, hereditary, and age-related conditions. Growing pet humanization is also encouraging owners to pursue regular health screening and timely diagnosis. The broad applicability of diagnostic products across routine examinations, disease surveillance, and specialized veterinary care supports consistent utilization. Increasing adoption of accurate, rapid, and minimally invasive testing further strengthens the segment's market position.

The Precision Veterinary Medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Precision Veterinary Medicine segment is predicted to witness the highest growth rate, because technological progress is enabling veterinarians to deliver increasingly individualized healthcare for dogs, cats, and other companion animals. Genomic analysis, molecular testing, bioinformatics, and targeted treatment strategies can help identify inherited risks, analyze diseases, guide therapeutic decisions, and improve clinical management. Rising cases of cancer and other complex chronic conditions are creating additional demand for precise biological information and specialized treatments. Advances in sequencing, computational analysis, and artificial intelligence are improving the practicality of precision-based veterinary solutions. At the same time, greater owner awareness and willingness to invest in sophisticated pet healthcare are supporting wider adoption of these technologies.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because the region has well-developed veterinary infrastructure, strong biotechnology capabilities, and extensive adoption of advanced companion-animal healthcare technologies. The presence of major animal-health companies, specialized diagnostic laboratories, research institutions, and sophisticated veterinary facilities creates a favorable environment for market development. Increasing pet ownership, greater spending on veterinary care, and rising interest in early disease detection and precision medicine are also strengthening demand. The United States remains a major contributor because of its established veterinary networks, strong research ecosystem, and growing use of molecular, genetic, and advanced diagnostic technologies for companion animals.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, as the region's companion-animal healthcare ecosystem continues to develop rapidly. Increasing numbers of pet owners, greater attention to animal welfare, rising veterinary expenditure, and improved access to specialized healthcare are encouraging adoption of advanced biotechnology solutions. Growth in diagnostic laboratories and

veterinary specialization is strengthening demand for molecular testing, genetic analysis, preventive care, and sophisticated disease-management technologies. Countries including China, India, Japan, South Korea, and Australia are contributing to regional expansion through improving veterinary capabilities and increasing investment in animal healthcare. The combination of expanding pet-care markets and technological advancement is creating significant growth potential for companion-animal biotechnology providers.

Key players in the market

Some of the key players in Companion Animal Biotechnology Market include Zoetis Inc., IDEXX Laboratories, Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Merck Animal Health, Virbac S.A., Dechra Pharmaceuticals Limited, Antech Diagnostics, Inc., Embark Veterinary, Inc., Basepaws, Orivet Genetic Pet Care, Animal Genetics Inc., VetStem, Inc., Animal Cell Therapies, Inc., FidoCure, ImpriMed, Inc., Regenera Sciences and Vetigenics.

Key Developments:

In June 2026, Elanco announced Elanco Ventures, backed by a \$25 million multi-year commitment, to invest in and advance innovation across animal health. The platform is intended to support strategic investments in therapeutic advancements and supportive technologies, creating a partnership and investment pathway for biotechnology innovators relevant to animal health, including companion-animal applications. In January 2026, Boehringer Ingelheim India entered into an agreement with Alivira Animal Health Limited for the distribution and promotion of its companion-animal portfolio in India.

Product Types Covered:

Diagnostic Products

Vaccines

Biologic Therapeutics

Genetic Testing Products

Cell Therapy Products

Gene Therapy Products

Regenerative Medicine Products

Microbiome-Based Products

Biotechnology Platforms Covered:

Genomics

Proteomics

Molecular Biotechnology

Cell Biotechnology

Gene Editing

Stem Cell Technology

Microbiome Biotechnology

Synthetic Biology

Bioinformatics

Animal Types Covered:

Dogs

Cats

Rabbits

Birds

Small Mammals

Reptiles

Exotic Companion Animals

Therapeutic Areas Covered:

Infectious Diseases

Oncology

Dermatological Disorders

Gastrointestinal Disorders

Orthopedic & Musculoskeletal Disorders

Cardiovascular Disorders

Neurological Disorders

Renal & Urinary Disorders

Respiratory Disorders

Endocrine & Metabolic Disorders

Immune-Mediated Disorders

Genetic & Hereditary Disorders

Ophthalmic Disorders

Distribution Channels Covered:

Veterinary Clinics & Hospitals

Veterinary Pharmacies

Specialty Animal Health Distributors

Online Veterinary Pharmacies

E-Commerce Channels

Direct-to-Consumer Channels

Diagnostic Technologies Covered:

Molecular Diagnostics

PCR-Based Diagnostics

Next-Generation Sequencing

Immunodiagnosics

Biomarker Diagnostics

Pathology-Based Diagnostics

Microbiome Diagnostics

Applications Covered:

Disease Diagnosis

Disease Prevention

Disease Treatment

Genetic Disease Screening

Precision Veterinary Medicine

Personalized Veterinary Medicine

Treatment Monitoring

Reproductive Biotechnology

End Users Covered:

Veterinary Hospitals

Veterinary Clinics

Veterinary Diagnostic Laboratories

Veterinary Specialty Centers

Veterinary Research Institutions

Academic Institutions

Biotechnology Companies

Animal Health Companies

Regions Covered:

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

2 RESEARCH FRAMEWORK

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
 - 2.4.1 Data Collection (Primary and Secondary)
 - 2.4.2 Data Modeling and Estimation Techniques
 - 2.4.3 Data Validation and Triangulation
 - 2.4.4 Analytical and Forecasting Approach

3 MARKET DYNAMICS AND TREND ANALYSIS

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

4 COMPETITIVE AND STRATEGIC ASSESSMENT

- 4.1 Porter's Five Forces Analysis
 - 4.1.1 Supplier Bargaining Power
 - 4.1.2 Buyer Bargaining Power
 - 4.1.3 Threat of Substitutes
 - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

5 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY PRODUCT TYPE

- 5.1 Diagnostic Products
- 5.2 Vaccines
- 5.3 Biologic Therapeutics
- 5.4 Genetic Testing Products
- 5.5 Cell Therapy Products
- 5.6 Gene Therapy Products
- 5.7 Regenerative Medicine Products
- 5.8 Microbiome-Based Products

6 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY BIOTECHNOLOGY PLATFORM

- 6.1 Genomics
- 6.2 Proteomics
- 6.3 Molecular Biotechnology
- 6.4 Cell Biotechnology
- 6.5 Gene Editing
- 6.6 Stem Cell Technology
- 6.7 Microbiome Biotechnology
- 6.8 Synthetic Biology
- 6.9 Bioinformatics

7 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY ANIMAL TYPE

- 7.1 Dogs
- 7.2 Cats
- 7.3 Rabbits
- 7.4 Birds
- 7.5 Small Mammals
- 7.6 Reptiles
- 7.7 Exotic Companion Animals

8 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY THERAPEUTIC AREA

- 8.1 Infectious Diseases
- 8.2 Oncology
- 8.3 Dermatological Disorders
- 8.4 Gastrointestinal Disorders
- 8.5 Orthopedic & Musculoskeletal Disorders
- 8.6 Cardiovascular Disorders
- 8.7 Neurological Disorders
- 8.8 Renal & Urinary Disorders
- 8.9 Respiratory Disorders
- 8.10 Endocrine & Metabolic Disorders
- 8.11 Immune-Mediated Disorders
- 8.12 Genetic & Hereditary Disorders
- 8.13 Ophthalmic Disorders

9 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY DISTRIBUTION CHANNEL

- 9.1 Veterinary Clinics & Hospitals
- 9.2 Veterinary Pharmacies
- 9.3 Specialty Animal Health Distributors
- 9.4 Online Veterinary Pharmacies
- 9.5 E-Commerce Channels
- 9.6 Direct-to-Consumer Channels

10 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY DIAGNOSTIC TECHNOLOGY

- 10.1 Molecular Diagnostics
- 10.2 PCR-Based Diagnostics
- 10.3 Next-Generation Sequencing
- 10.4 Immunodiagnosics
- 10.5 Biomarker Diagnostics
- 10.6 Pathology-Based Diagnostics
- 10.7 Microbiome Diagnostics

11 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY APPLICATION

- 11.1 Disease Diagnosis
- 11.2 Disease Prevention
- 11.3 Disease Treatment
- 11.4 Genetic Disease Screening
- 11.5 Precision Veterinary Medicine
- 11.6 Personalized Veterinary Medicine
- 11.7 Treatment Monitoring
- 11.8 Reproductive Biotechnology

12 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY END USER

- 12.1 Veterinary Hospitals
- 12.2 Veterinary Clinics
- 12.3 Veterinary Diagnostic Laboratories
- 12.4 Veterinary Specialty Centers
- 12.5 Veterinary Research Institutions
- 12.6 Academic Institutions
- 12.7 Biotechnology Companies
- 12.8 Animal Health Companies

13 GLOBAL COMPANION ANIMAL BIOTECHNOLOGY MARKET, BY GEOGRAPHY

- 13.1 North America
 - 13.1.1 United States
 - 13.1.2 Canada
 - 13.1.3 Mexico
- 13.2 Europe
 - 13.2.1 United Kingdom
 - 13.2.2 Germany
 - 13.2.3 France
 - 13.2.4 Italy
 - 13.2.5 Spain
 - 13.2.6 Netherlands
 - 13.2.7 Belgium
 - 13.2.8 Sweden
 - 13.2.9 Switzerland
 - 13.2.10 Poland
 - 13.2.11 Rest of Europe

13.3 Asia Pacific

13.3.1 China

13.3.2 Japan

13.3.3 India

13.3.4 South Korea

13.3.5 Australia

13.3.6 Indonesia

13.3.7 Thailand

13.3.8 Malaysia

13.3.9 Singapore

13.3.10 Vietnam

13.3.11 Rest of Asia Pacific

13.4 South America

13.4.1 Brazil

13.4.2 Argentina

13.4.3 Colombia

13.4.4 Chile

13.4.5 Peru

13.4.6 Rest of South America

13.5 Rest of the World (RoW)

13.5.1 Middle East

13.5.1.1 Saudi Arabia

13.5.1.2 United Arab Emirates

13.5.1.3 Qatar

13.5.1.4 Israel

13.5.1.5 Rest of Middle East

13.5.2 Africa

13.5.2.1 South Africa

13.5.2.2 Egypt

13.5.2.3 Morocco

13.5.2.4 Rest of Africa

14 STRATEGIC MARKET INTELLIGENCE

14.1 Industry Value Network and Supply Chain Assessment

14.2 White-Space and Opportunity Mapping

14.3 Product Evolution and Market Life Cycle Analysis

14.4 Channel, Distributor, and Go-to-Market Assessment

15 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES

- 15.1 Mergers and Acquisitions
- 15.2 Partnerships, Alliances, and Joint Ventures
- 15.3 New Product Launches and Certifications
- 15.4 Capacity Expansion and Investments
- 15.5 Other Strategic Initiatives

16 COMPANY PROFILES

- 16.1 Zoetis Inc.
- 16.2 IDEXX Laboratories, Inc.
- 16.3 Boehringer Ingelheim Animal Health
- 16.4 Elanco Animal Health Incorporated
- 16.5 Merck Animal Health
- 16.6 Virbac S.A.
- 16.7 Dechra Pharmaceuticals Limited
- 16.8 Antech Diagnostics, Inc.
- 16.9 Embark Veterinary, Inc.
- 16.10 Basepaws
- 16.11 Orivet Genetic Pet Care
- 16.12 Animal Genetics Inc.
- 16.13 VetStem, Inc.
- 16.14 Animal Cell Therapies, Inc.
- 16.15 FidoCure
- 16.16 Imprimed, Inc.
- 16.17 Regenera Sciences
- 16.18 Vetigenics

List Of Tables

LIST OF TABLES

Table 1 Global Companion Animal Biotechnology Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Companion Animal Biotechnology Market Outlook, By Product Type (2023-2034) (\$MN)

Table 3 Global Companion Animal Biotechnology Market Outlook, By Diagnostic Products (2023-2034) (\$MN)

Table 4 Global Companion Animal Biotechnology Market Outlook, By Vaccines (2023-2034) (\$MN)

Table 5 Global Companion Animal Biotechnology Market Outlook, By Biologic Therapeutics (2023-2034) (\$MN)

Table 6 Global Companion Animal Biotechnology Market Outlook, By Genetic Testing Products (2023-2034) (\$MN)

Table 7 Global Companion Animal Biotechnology Market Outlook, By Cell Therapy Products (2023-2034) (\$MN)

Table 8 Global Companion Animal Biotechnology Market Outlook, By Gene Therapy Products (2023-2034) (\$MN)

Table 9 Global Companion Animal Biotechnology Market Outlook, By Regenerative Medicine Products (2023-2034) (\$MN)

Table 10 Global Companion Animal Biotechnology Market Outlook, By Microbiome-Based Products (2023-2034) (\$MN)

Table 11 Global Companion Animal Biotechnology Market Outlook, By Biotechnology Platform (2023-2034) (\$MN)

Table 12 Global Companion Animal Biotechnology Market Outlook, By Genomics (2023-2034) (\$MN)

Table 13 Global Companion Animal Biotechnology Market Outlook, By Proteomics (2023-2034) (\$MN)

Table 14 Global Companion Animal Biotechnology Market Outlook, By Molecular Biotechnology (2023-2034) (\$MN)

Table 15 Global Companion Animal Biotechnology Market Outlook, By Cell Biotechnology (2023-2034) (\$MN)

Table 16 Global Companion Animal Biotechnology Market Outlook, By Gene Editing (2023-2034) (\$MN)

Table 17 Global Companion Animal Biotechnology Market Outlook, By Stem Cell Technology (2023-2034) (\$MN)

Table 18 Global Companion Animal Biotechnology Market Outlook, By Microbiome

Biotechnology (2023-2034) (\$MN)

Table 19 Global Companion Animal Biotechnology Market Outlook, By Synthetic Biology (2023-2034) (\$MN)

Table 20 Global Companion Animal Biotechnology Market Outlook, By Bioinformatics (2023-2034) (\$MN)

Table 21 Global Companion Animal Biotechnology Market Outlook, By Animal Type (2023-2034) (\$MN)

Table 22 Global Companion Animal Biotechnology Market Outlook, By Dogs (2023-2034) (\$MN)

Table 23 Global Companion Animal Biotechnology Market Outlook, By Cats (2023-2034) (\$MN)

Table 24 Global Companion Animal Biotechnology Market Outlook, By Rabbits (2023-2034) (\$MN)

Table 25 Global Companion Animal Biotechnology Market Outlook, By Birds (2023-2034) (\$MN)

Table 26 Global Companion Animal Biotechnology Market Outlook, By Small Mammals (2023-2034) (\$MN)

Table 27 Global Companion Animal Biotechnology Market Outlook, By Reptiles (2023-2034) (\$MN)

Table 28 Global Companion Animal Biotechnology Market Outlook, By Exotic Companion Animals (2023-2034) (\$MN)

Table 29 Global Companion Animal Biotechnology Market Outlook, By Therapeutic Area (2023-2034) (\$MN)

Table 30 Global Companion Animal Biotechnology Market Outlook, By Infectious Diseases (2023-2034) (\$MN)

Table 31 Global Companion Animal Biotechnology Market Outlook, By Oncology (2023-2034) (\$MN)

Table 32 Global Companion Animal Biotechnology Market Outlook, By Dermatological Disorders (2023-2034) (\$MN)

Table 33 Global Companion Animal Biotechnology Market Outlook, By Gastrointestinal Disorders (2023-2034) (\$MN)

Table 34 Global Companion Animal Biotechnology Market Outlook, By Orthopedic & Musculoskeletal Disorders (2023-2034) (\$MN)

Table 35 Global Companion Animal Biotechnology Market Outlook, By Cardiovascular Disorders (2023-2034) (\$MN)

Table 36 Global Companion Animal Biotechnology Market Outlook, By Neurological Disorders (2023-2034) (\$MN)

Table 37 Global Companion Animal Biotechnology Market Outlook, By Renal & Urinary Disorders (2023-2034) (\$MN)

Table 38 Global Companion Animal Biotechnology Market Outlook, By Respiratory Disorders (2023-2034) (\$MN)

Table 39 Global Companion Animal Biotechnology Market Outlook, By Endocrine & Metabolic Disorders (2023-2034) (\$MN)

Table 40 Global Companion Animal Biotechnology Market Outlook, By Immune-Mediated Disorders (2023-2034) (\$MN)

Table 41 Global Companion Animal Biotechnology Market Outlook, By Genetic & Hereditary Disorders (2023-2034) (\$MN)

Table 42 Global Companion Animal Biotechnology Market Outlook, By Ophthalmic Disorders (2023-2034) (\$MN)

Table 43 Global Companion Animal Biotechnology Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 44 Global Companion Animal Biotechnology Market Outlook, By Veterinary Clinics & Hospitals (2023-2034) (\$MN)

Table 45 Global Companion Animal Biotechnology Market Outlook, By Veterinary Pharmacies (2023-2034) (\$MN)

Table 46 Global Companion Animal Biotechnology Market Outlook, By Specialty Animal Health Distributors (2023-2034) (\$MN)

Table 47 Global Companion Animal Biotechnology Market Outlook, By Online Veterinary Pharmacies (2023-2034) (\$MN)

Table 48 Global Companion Animal Biotechnology Market Outlook, By E-Commerce Channels (2023-2034) (\$MN)

Table 49 Global Companion Animal Biotechnology Market Outlook, By Direct-to-Consumer Channels (2023-2034) (\$MN)

Table 50 Global Companion Animal Biotechnology Market Outlook, By Diagnostic Technology (2023-2034) (\$MN)

Table 51 Global Companion Animal Biotechnology Market Outlook, By Molecular Diagnostics (2023-2034) (\$MN)

Table 52 Global Companion Animal Biotechnology Market Outlook, By PCR-Based Diagnostics (2023-2034) (\$MN)

Table 53 Global Companion Animal Biotechnology Market Outlook, By Next-Generation Sequencing (2023-2034) (\$MN)

Table 54 Global Companion Animal Biotechnology Market Outlook, By Immunodiagnosics (2023-2034) (\$MN)

Table 55 Global Companion Animal Biotechnology Market Outlook, By Biomarker Diagnostics (2023-2034) (\$MN)

Table 56 Global Companion Animal Biotechnology Market Outlook, By Pathology-Based Diagnostics (2023-2034) (\$MN)

Table 57 Global Companion Animal Biotechnology Market Outlook, By Microbiome

Diagnostics (2023-2034) (\$MN)

Table 58 Global Companion Animal Biotechnology Market Outlook, By Application (2023-2034) (\$MN)

Table 59 Global Companion Animal Biotechnology Market Outlook, By Disease Diagnosis (2023-2034) (\$MN)

Table 60 Global Companion Animal Biotechnology Market Outlook, By Disease Prevention (2023-2034) (\$MN)

Table 61 Global Companion Animal Biotechnology Market Outlook, By Disease Treatment (2023-2034) (\$MN)

Table 62 Global Companion Animal Biotechnology Market Outlook, By Genetic Disease Screening (2023-2034) (\$MN)

Table 63 Global Companion Animal Biotechnology Market Outlook, By Precision Veterinary Medicine (2023-2034) (\$MN)

Table 64 Global Companion Animal Biotechnology Market Outlook, By Personalized Veterinary Medicine (2023-2034) (\$MN)

Table 65 Global Companion Animal Biotechnology Market Outlook, By Treatment Monitoring (2023-2034) (\$MN)

Table 66 Global Companion Animal Biotechnology Market Outlook, By Reproductive Biotechnology (2023-2034) (\$MN)

Table 67 Global Companion Animal Biotechnology Market Outlook, By End User (2023-2034) (\$MN)

Table 68 Global Companion Animal Biotechnology Market Outlook, By Veterinary Hospitals (2023-2034) (\$MN)

Table 69 Global Companion Animal Biotechnology Market Outlook, By Veterinary Clinics (2023-2034) (\$MN)

Table 70 Global Companion Animal Biotechnology Market Outlook, By Veterinary Diagnostic Laboratories (2023-2034) (\$MN)

Table 71 Global Companion Animal Biotechnology Market Outlook, By Veterinary Specialty Centers (2023-2034) (\$MN)

Table 72 Global Companion Animal Biotechnology Market Outlook, By Veterinary Research Institutions (2023-2034) (\$MN)

Table 73 Global Companion Animal Biotechnology Market Outlook, By Academic Institutions (2023-2034) (\$MN)

Table 74 Global Companion Animal Biotechnology Market Outlook, By Biotechnology Companies (2023-2034) (\$MN)

Table 75 Global Companion Animal Biotechnology Market Outlook, By Animal Health Companies (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

I would like to order

Product name: Companion Animal Biotechnology Market Forecasts To 2034 – Global Analysis By Product Type (Diagnostic Products, Vaccines, Biologic Therapeutics, Genetic Testing Products, Cell Therapy Products, Gene Therapy Products, Regenerative Medicine Products and Microbiome-Based Products), Biotechnology Platform, Animal Type, Therapeutic Area, Distribution Channel, Diagnostic Technology, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/C88639422A32EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C88639422A32EN.html>